1 / 15

Is vaccination a valuable preventive strategy?

Cost-effectiveness of pneumococcal vaccination for older people: a study in five western European countries. Ament A, Baltussen R, Duru G, Rigaud-Bully C, De Graeve D, et al , Journal of infectious diseases, Clinical Infectious Diseases, vol 31, nr 2, pp 444-50.

kami
Télécharger la présentation

Is vaccination a valuable preventive strategy?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Cost-effectiveness of pneumococcal vaccination for older people: a study in five western European countries Ament A, Baltussen R, Duru G, Rigaud-Bully C, De Graeve D, et al, Journal of infectious diseases, Clinical Infectious Diseases, vol 31, nr 2, pp 444-50

  2. Is vaccination a valuable preventive strategy? • Pneumococcal Pneumonia is a serious threat to our health • Treatment of Pneumococcal pneumonia is costly • This is especially true in the elderly • Vaccination can eliminate part of the clinical and economic consequences of pneumococcal disease • But it generates costs as well (vaccine, administration, side-effects…)  Analyse the cost-effectiveness of vaccination

  3. Restriction to invasive disease – Analysis in five countries • Much better evidence of clinical protection of the vaccine against invasive disease • Information on the cost-effectiveness of vaccination in preventing invasive disease could provide strong support for public policies to provide strong support for public policies to vaccinate older individuals • Belgium France, Scotland, Spain and Sweden; same methodology, different data

  4. Characteristics of the evaluation • Alternatives compared: • vaccination versus treatment of persons 64+ years • Measures of costs and effects • Costs (C): direct medical costs for society in € 1995 • Effects (E): number of qualys gained • CE-ratio: C (Vaccination) - C (Treatment ) E (Vaccination) - E (Treatment)

  5. Year 1 …year five Country-specific, age specific mortality rates

  6. Results of the sensitivity analyses

  7. Results of the sensitivity analyses

  8. Conclusions • The results support recent recommendations to vaccinate people aged 65 years and older with Pneumococcal P.S. Vaccine • Even when only considering invasive disease, this strategy is acceptably to moderately cost-effective (less so for the very old) • Very reliable data on incidence and mortality of S. pneumoniae would be good to convince the sceptics

More Related